New drug combo takes on advanced cancers in first human trial

NCT ID NCT06470763

Completed Disease control Sponsor: Anaveon AG Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This early-phase study tests an experimental drug called ANV600, given alone or with the immunotherapy Keytruda, in 240 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the drug can shrink tumors. Because it is a first-in-human trial, the results will help decide if further testing is warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ANV600 (an experimental drug) and pembrolizumab (Keytruda)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early first-in-human study, so safety and effectiveness are not yet known. Many experimental drugs fail in early trials, and participants may experience side effects without benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

CEPCM - AP-HM Hopital de la Timone

Marseille, France
Cantonal Hospital St Gallen

Sankt Gallen, Switzerland
Charite Universitaetsmedizin Berlin

Berlin, Germany
Clinica Universidad de Navarra - Pamplona

Pamplona, Spain
Cliniques Universitaires Saint-Luc

Brussels, Belgium
Ente Ospedaliero Cantonale - Istituto Oncologico della Svizzera Italiana

Bellinzona, Switzerland
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
INCLIVA Foundation

Valencia, Spain
Institut Bergonie

Bordeaux, France
Institut Gustave Roussy

Villejuif, France
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Krankenhaus Nordwest - Institut für Klinisch-Onkologische Forschung (IKF)

Frankfurt, Germany
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)

Amsterdam, Netherlands
Oncopole Claudius Regaud, Toulouse

Toulouse, France
START Madrid CIOCC

Madrid, Spain
Universitaetsmedizin der Johannes Gutenberg - Universitaet Mainz

Mainz, Germany
Vall d'Hebron Institute of Oncology (VHIO)

Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.